亚博APP手机登录|首页

Press Release
  • Press Release
  • Contact Us
  • CStone announced that the research data of CS5001 (ROR1 ADC) has been selected as a late-breaking abstract to be presented at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021, Boston, USA

    Times:2021.09.28   Author:CStone

    Suzhou, China, September, 28, 2021 - CStone Pharmaceuticals (“CStone”, HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the data on the preclinical characterization of the potentially global best-in-class drug CS5001(ROR1 ADC) has been selected in a late-breaking abstract (LBA) session as a virtual poster presentation at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021. The results show that CS5001 is a promising therapeutic candidate for ROR1-expressing hematological and solid malignancies with precision medicine potential. The work was collaboratively accomplished by CStone, LegoChem Biosciences (“LCB”), Inc., Daejeon, Republic of Korea and ABL Bio, Seongnam, Republic of Korea.

    • Presentation session: Multiple solid and hematological malignancies
    • Date: October 7-10, 2021
    • Format: Late-breaking abstract (LBA)
    • Title: CS5001, a novel ROR1-targeting antibody drug conjugate (ADC) armed with tumor-cleavable β-glucuronide linkers and pyrrolobenzodiazepine (PBD) prodrugs for hematological and solid malignancies
    • Speakers/Leading Principal Investigator: Dr. Archie N. Tse, Chief Scientific Officer of CStone

     

    CS5001 is a pre-clinical antibody-drug conjugate (ADC) completing Investigational New Drug (“IND”) enabling studies. It targets ROR1 (receptor tyrosine kinase-like orphan receptor 1), a high-potential ADC target for multiple solid and hematological malignancies. ROR1 protein expression is prevalent in a variety of cancers including various forms of leukemia, non-Hodgkin lymphoma, and breast, lung and ovarian cancers, and largely absent in normal adult tissues.

    CS5001 has a uniquely design tumor-cleavable linker that is conjugated to a LCB’s proprietary pyrrolobenzodiazepine (PBD) prodrug. Only after reaching the tumor, the linker and prodrug are cleaved to release the PBD toxin, resulting in lethal DNA cross-links in cancer cells. The use of the linker plus PBD prodrug effectively helps addressing the toxicity problem associated with traditional PBD payloads, leading to a better safety profile. Additionally, CS5001 utilizes site-specific conjugation for a precise drug antibody ratio of 2 which enables homogeneous production and large-scale manufacturing.

    In October 2020, CStone signed a licensing agreement with LCB for the development and commercialization of CS5001. Under the agreement, CStone obtains the exclusive global right to lead development and commercialization of CS5001 outside the Republic of Korea.

    ***

    About CStone

    CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received three drug approvals in Greater China, including two in Mainland China and one in Taiwan. CStone's vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

    For more information about CStone, please visit: www.cstonepharma.com.

    Forward-looking statement

    The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.

    Your privacy is important for us. We use cookies to enhance your experience when visiting our websites: performance cookies show us how you use this website, functional cookies remember your preferences and targeting cookies help us to share content relevant to you. Select “Accept all” for giving your consent to all cookies or select “Reject all” for using only strictly necessary cookies.